CAMBRIDGE, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that additional clinical experience of the Company’s AUGMENTSM treatment demonstrated improved pregnancy rates in women who had failed three to seven prior in vitro fertilization (IVF) cycles. These results were reported at the Society for Reproductive Investigation (SRI) 62nd Annual Scientific Meeting being held in San Francisco, CA. The AUGMENT treatment is not available in the United States.
Help employers find you! Check out all the jobs and post your resume.
